tiprankstipranks
pc:cam4a

cAMPfield

cAMPfield is a biopharmaceutical company developing prifemilast, a potentially best-in-class oral PDE4 inhibitor for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease. The company in-licensed prifemilast from Newsoara Biopharma and was founded by Mountainfield Venture Partners alongside industry executives who played key roles in the development and commercialization of major biologics.

Leadership & Board

Currently, no data available

Latest Estimated Valuation

Estimated Valuation
Estimated Valuation
Total Amount Raised$180M
Total Amount Raised$180M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$180M
Latest Funding Amount$180M
Latest Funding RoundSeries A
Latest Funding RoundSeries A
Post-Money Valuation
Post-Money Valuation

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Jun 18, 2026
Series A
$180.00M

Investors

Investor Name
Funding Round

Related News and Analysis